OraSure Technologies, Inc. — Q3 2023 Form 10-Q
Reporting period: Three and nine months ended September 30, 2023. OraSure develops and sells diagnostic tests, specimen-collection products, and related laboratory services. In February 2023, it combined its former Diagnostics and Molecular Solutions operations into one reportable segment.
Financial performance and position
| Metric | Q3 2023 | Q3 2022 | Nine months 2023 | Nine months 2022 |
|---|---|---|---|---|
| Net revenue | $89.2 million | $116.5 million | $329.6 million | $264.4 million |
| Gross profit | $44.3 million | $46.5 million | $136.5 million | $98.6 million |
| Gross margin | 49.7% | 39.9% | 41.4% | 37.3% |
| Operating income (loss) | $10.9 million | $0.9 million | $28.8 million | $(36.8) million |
| Net income (loss) | $11.2 million | $5.6 million | $33.6 million | $(32.9) million |
| Diluted EPS | $0.15 | $0.08 | $0.45 | $(0.45) |
- Revenue mix and trends: Q3 revenue fell 23%, chiefly as COVID-19 Diagnostics revenue declined 37% to $50.1 million, largely due to lower InteliSwab sales under U.S. government procurement contracts. HIV/other Diagnostics revenue rose 59% to $19.6 million. For the first nine months, revenue grew 25%, led by COVID-19 Diagnostics (+49%) and Diagnostics (+50%); Molecular Products fell 20% and COVID-19 Molecular Products fell 97%.
- Margins and expenses: Management attributed improved margins to InteliSwab manufacturing efficiencies and packaging changes, less scrap, and lower freight costs. Cost reductions and lower impairment losses supported operating income. Nine-month results included $7.5 million of impairment charges and $6.9 million of accelerated depreciation in Q2 related to shortened useful lives of Thailand InteliSwab production equipment.
- Cash flow: Operating activities generated $100.2 million in the first nine months, versus $29.2 million used in the prior-year period. Cash and cash equivalents were $217.5 million at September 30, 2023, and short-term investments were $7.4 million. Working capital was $315.5 million. Investing activities provided $35.6 million and financing activities used $2.7 million.
- Debt and liquidity: The filing reports no conventional borrowings. Finance lease liabilities totaled $1.2 million and operating lease liabilities $13.8 million. Total liabilities were $53.5 million. Management expects existing cash to fund operating expenses and capital needs for at least the next 12 months.
Material changes, outlook, and risks
- Q3 revenue declined despite strong nine-month growth, reflecting reduced government-contract COVID-19 test sales. Management expects that decline to continue in Q4, but at a lower rate. It expects Q4 gross margins to moderate from Q3 levels as product mix shifts, including lower InteliSwab volume. The filing provides no numerical full-year revenue or earnings guidance.
- OraSure received $84.6 million of the $109.0 million U.S. government manufacturing-capacity contract funding by September 30; the remaining $24.4 million was received in October 2023 after final validation testing. Government-contract reimbursement timing is among the factors that could affect cash requirements.
- In Q3, the company recorded a $6.2 million impairment of Diversigen and Novosanis intangible assets. It also recorded $1.3 million of equipment and leasehold-improvement impairments during the first nine months. Management cited demand changes and its decision not to proceed with certain laboratory improvements.
- A single non-commercial customer represented 56% of Q3 revenue, 66% of nine-month revenue, and 52% of accounts receivable at quarter-end, creating significant customer concentration. The company also relies on sole-source vendors for certain products and critical components.
- Disclosure controls were deemed ineffective because a material weakness in customer-pricing validation within revenue recognition allowed inaccurate pricing to affect revenue during the six months ended June 30, 2023. The company said the nine-month financial statements were not misstated and a remediation plan was being implemented.
- OraSure is appealing a district court summary judgment of noninfringement in its patent litigation with Spectrum Solutions. Patent-office reviews and motions for sanctions were also pending; management said ordinary-course legal matters were not expected to have a material adverse effect.
- Other risks highlighted include the ability to meet government-contract commitments, changing COVID-19 demand, customer ordering patterns, product acceptance and regulatory compliance, competition, cybersecurity, and maintaining profitability.
Important facts for investors to verify
- Progress and timing of InteliSwab manufacturing transition to Pennsylvania, government-contract milestones, and related remaining funding.
- Whether COVID-19 sales decline and expected Q4 margin moderation align with management’s commentary.
- Customer concentration, receivable collection, and purchasing trends among major customers.
- Remediation and testing of the revenue-pricing control weakness.
- Further impairment charges, operating cash generation, and the extent to which working-capital changes drove cash flow.
- Developments in the Spectrum patent appeal and related patent-office proceedings.